Abcuro is an immuno-therapeutic company aiming to help treat cancer and autoimmune diseases. Using pre-clinical antibody development, Abcuro develops clinical treatments that target lektin receptors on cytotoxic T cells. Other advancements being made in the company include the ABC015 anti-KLRG1 blocking antibody. Abcuro was founded by Stefano Gullà in 2015 and is headquartered in Boston, MA.

Register for Details

For more details on financing and valuation for Abcuro, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Learn more about Abcuro

plusminus

Can you invest in Abcuro pre-IPO?

Abcuro is a privately held company and is not publicly traded, therefore investing in Abcuro pre-IPO is only available to accredited investors. If you meet the accreditation criteria, you can learn more about Forge’s Secondary Marketplace and how to invest in private companies before their potential IPO. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

Can you sell shares of Abcuro before it goes public?

You can seek to sell your shares in Abcuro while it remains private. If you are considering selling, you can register today for free to get started. Once registered, a Private Market Specialist will guide you through any questions you might have. You may also continue to browse through our resources to help you understand the implications and procedures involved in selling your private market shares.
plusminus

What is the pre-IPO value of my Abcuro shares?

To determine the value of your Abcuro shares, create a free account to gain access to Forge’s platform. In addition to the Forge Price, Forge Markets contains pricing information for hundreds of pre-IPO companies such as Last Closed Trade Price. A Private Market Specialist will also be available to assist you with any inquiries related to your Abcuro shares. You can also learn more about how to sell your private shares before getting started.
plusminus

Is Abcuro a publicly traded company?

If you are interested in buying or selling private company shares, you can register with Forge today for free to explore your options. Registering gives you access to one of our Private Market Specialists who can guide you through the process of buying or selling. Learn more about how Forge might help you buy pre-IPO shares or sell pre-IPO shares.
plusminus

Will Abcuro go IPO?

Abcuro has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2024.
plusminus

What is Abcuro’s IPO price?

The Abcuro IPO price does not exist at this time, as Abcuro is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Abcuro register for Forge Markets, today.
plusminus

When was Abcuro founded?

Abcuro was founded in 2015.
plusminus

What is Abcuro funding to date?

Abcuro has raised $207.25MM to date.

Who are Abcuro’s major investors?

Undisclosed Investors
Soleus Capital
Kaitai Capital
Sanofi Ventures
Eurofarma
Redmile Group
Samsara Biocapital
New Leaf Ventures
Bain Capital Life Sciences
Pontifax
Hongsen Investment Group
Partners Innovation Fund
Shangpharma Innovation
Tekla Capital Management
Ra Capital Management
Mass General Brigham Ventures

Abcuro Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
08/17/2023 Series B-1 $33.13MM $xx.xx $307.61MM Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital
Price per Share
$xx.xx
Shares Outstanding
7,542,862
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital
08/17/2023 Series B $121.87MM $xx.xx $307.61MM Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital
Price per Share
$xx.xx
Shares Outstanding
22,200,405
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Redmile Group, Bain Capital Life Sciences, RA Capital Management, Samsara BioCapital, Sanofi Ventures, New Leaf Ventures, Pontifax, Tekla Capital Management, Mass General Brigham Ventures, Eurofarma, Soleus Capital
01/07/2021 Series A-1 $42MM $xx.xx $77.96MM Sanofi Ventures, Mass General Brigham Ventures, Pontifax, Hongsen Investment Group, RA Capital Management, Samsara BioCapital
Price per Share
$xx.xx
Shares Outstanding
7,650,686
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
Sanofi Ventures, Mass General Brigham Ventures, Pontifax, Hongsen Investment Group, RA Capital Management, Samsara BioCapital
11/09/2018 Series A $8MM $xx.xx $18.86MM ShangPharma Innovation, Partners Innovation Fund, Kaitai Capital
Price per Share
$xx.xx
Shares Outstanding
1,619,201
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
2.0
Key Investors
ShangPharma Innovation, Partners Innovation Fund, Kaitai Capital
11/30/2016 Series Seed $2.25MM $xx.xx $5.62MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
671,141
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Participating
Participation Cap
3.0
Key Investors
Undisclosed Investors
Updated on: Nov 5, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.